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AbsTrACT
Objective antireflux surgery can be proposed in patients 
with gOrD, especially when proton pump inhibitor (PPi) 
use leads to incomplete symptom improvement. However, 
to date, international consensus guidelines on the clinical 
criteria and additional technical examinations used in patient 
selection for antireflux surgery are lacking. We aimed at 
generating key recommendations in the selection of patients 
for antireflux surgery.
Design We included 35 international experts 
(gastroenterologists, surgeons and physiologists) in a 
Delphi process and developed 37 statements that were 
revised by the consensus group, to start the Delphi process. 
three voting rounds followed where each statement was 
presented with the evidence summary. the panel indicated 
the degree of agreement for the statement. When 80% 
of the consensus group agreed (a+/a) with a statement, 
this was defined as consensus. all votes were mutually 
anonymous.
results Patients with heartburn with a satisfactory 
response to PPis, patients with a hiatal hernia (HH), patients 
with oesophagitis los angeles (la) grade B or higher and 
patients with Barrett’s oesophagus are good candidates for 
antireflux surgery. an endoscopy prior to antireflux surgery 
is mandatory and a barium swallow should be performed 
in patients with suspicion of a HH or short oesophagus. 
Oesophageal manometry is mandatory to rule out major 
motility disorders. Finally, oesophageal pH (±impedance) 
monitoring of PPi is mandatory to select patients for 
antireflux surgery, if endoscopy is negative for unequivocal 
reflux oesophagitis.
Conclusion With the icarUS guidelines, we generated 
key recommendations for selection of patients for antireflux 
surgery.
InTrODuCTIOn
GORD occurs when the reflux of (duodeno)-gastric 
contents into the oesophagus causes troublesome 
symptoms and/or tissue damage (oesophagitis, 
stricture, Barrett’s oesophagus).1 GORD is a very 
common condition with a prevalence of 20% in the 
Western population. It may present with a broad 
spectrum of symptoms, subdivided into typical, 
oesophageal manifestations (heartburn and regurgi-
tation) and a variety of atypical, extra-oesophageal 
symptoms, such as chronic cough, wheezing and 
significance of this study
What is already known on this subject?
 ► Anti-reflux surgery is suggested in a subgroup 
of patients having gastro-esophageal reflux 
disease.
 ► Selecting patients for anti-reflux surgery 
however is not straightforward.
What are the new findings?
 ► Based on several statements that generated 
consensus, a number of recommendations can 
be made for selecting patients for anti-reflux 
surgery.
 ► All patients require endoscopy, pH-monitoring 
off PPI and esophageal manometry.
How might it impact on clinical practice in the 
foreseeable future?
 ► Referring a patient for anti-reflux surgery has to 
be an informed decision process, based on both 
positive and negative supporting findings.
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hoarseness. Typical and atypical symptoms can coexist in the 
same patient.2–4 
Proton pump inhibitors (PPIs) are the first-line medical treat-
ment for patients with GORD, and PPI therapy has proven to 
be highly effective in healing oesophagitis.5 6 However, efficacy 
rates for symptom relief are significantly lower, with between 
10% and 40% of patients with GORD failing to respond symp-
tomatically, either partially or completely.6 Underlying mecha-
nisms behind symptom generation in refractory GORD are the 
presence of weakly acidic and bile reflux, residual acid reflux, 
oesophageal hypersensitivity and psychological comorbidities.6
When lifestyle modifications, dietary changes and especially 
when medical treatment (antacids, histamine 2 (H2-) receptor 
antagonist and PPIs) for GORD fails, antireflux surgery can be 
proposed. Antireflux surgery can also be recommended in case 
of intolerance to PPIs or as an alternative in anticipated long-
term medical therapy in young patients with GORD. While 
medical treatment is focused on reducing the acidity of the 
refluxate, classic antireflux surgery generates a mechanical and 
functional barrier preventing reflux from gastric contents into 
the oesophagus.
Several long-term follow-up studies looking at recurrence 
rates of reflux symptoms have been published over the last 
years. A recent Swedish study followed 2655 patients who 
underwent primary laparoscopic antireflux surgery for a mean 
of 5.1 years and demonstrated recurrence of reflux in 470 
(17.7%) of patients. Risk factors for recurrence of reflux were 
female gender, older age and comorbidity.7 A 5-year follow-up 
study, the LOTUS trial (Long-Term Usage of Esomeprazole vs 
Surgery for Treatment of Chronic Gastro-oesophageal Reflux 
Disease), demonstrated that a standardised laparoscopic Nissen 
fundoplication performed in expert centres and treatment with 
esomeprazole had similar outcome results concerning treatment 
failure rate, although that relief of heartburn was somewhat 
superior after surgery. The vast majority of patients achieved and 
remained in remission after 5 years, both in the surgical group as 
well as in the medical treatment group.8 However, the LOTUS 
study only enrolled patients with complete symptom control on 
esomeprazole and the results are not necessarily applicable to 
the group of patients with insufficient symptom control on PPIs, 
which constitutes a risk factor for a poor outcome.9
Selection of patients for antireflux surgery is traditionally 
based on the symptom pattern (preferably typical GORD symp-
toms), on the response to PPIs (at least partial response) and 
on the result of oesophageal pH or pH-impedance monitoring 
(pathological acid exposure in the absence of acid suppres-
sive therapy).9 10 In 2013, a US-based consensus concerning 
preoperative diagnostic workup before antireflux surgery was 
published; however, this was a national consensus (the expert 
panel consisted of only American experts), achieved through 
informal voting.11
The literature reports that outcome of antireflux surgery 
is influenced not only by anatomical and technical aspects, as 
assessed by endoscopy, radiology, manometry and reflux moni-
toring, but also by demographic and comorbidity factors such 
as the presence of IBS, functional dyspepsia (FD), anxiety and 
depression. However, it is unclear to which extent these aspects 
should influence decisions to perform antireflux surgery, and 
to date, global consensus guidelines on the clinical criteria and 
additional technical examinations used in patient selection for 
antireflux surgery are lacking.
Therefore, the aim of this project was to develop a global and 
multidisciplinary consensus on patient characteristics and preop-
erative examinations that could offer the clinician guidance in 
selecting adult patients with GORD for classic antireflux surgery 
and possibly in adapting the technical aspects of the intervention 
in order to optimise clinical outcome.
MeTHODs
A Delphi process was started, with support from the Interna-
tional Society for Diseases of the Oesophagus (ISDE), to develop 
consensus statements for preoperative investigations and their 
results in the selection of adult patients for antireflux surgery. 
This approach combines the principles of evidence-based medi-
cine, supported by systematic literature reviews and the use of a 
voting process. This method is increasingly used in healthcare as 
a rigorous means of determining consensus for complex prob-
lems in medicine for which evidence from controlled trials is 
lacking.1 12–15
The principal steps in the process were: (1) selection of an 
international Consensus Group consisting of several experts 
in GORD management with different clinical and scientific 
backgrounds to contribute to this expert panel; (2) develop-
ment of draft statements by a Working Group composed of five 
Consensus Group experts with varied backgrounds; (3) system-
atic literature reviews to identify evidence to support each state-
ment; (4) three rounds of repeated voting of the statements and 
voting discussion until a stable level of consensus voting was 
reached and (5) grading of the strength using accepted criteria.16
For the Consensus Group, which comprised the Working 
Group, 42 international experts with demonstrated knowledge/
expertise were invited, and 35 from 15 countries (Australia, 
Belgium, Brazil, Canada, Denmark, France, Italy, Japan, Neth-
erlands, Norway, Sweden, Switzerland, Turkey, UK and USA) 
agreed to participate. The group, consisting of gastroenterolo-
gists, surgeons and physiologists, combined a diversity of views 
and expertise related to GORD diagnosis and management.
We conducted a systematic literature search using a number of 
relevant keywords (MeSH: antireflux surgery and manometry/
endoscopy/ pH-metry/gastric emptying/comorbidities/ barium 
X-ray). A core panel of five members reviewed the list of publi-
cations and identified the ones relevant to the process. These 
were stored in PDF format on a central server to which Delphi 
panel members had access. The references cited in this chapter 
are only a selection of the articles reviewed in each area and were 
selected to clarify the discussion.
The Working Group developed an initial 27 statements and 
prepared and reviewed the evidence to support the statements 
that were presented to the Consensus Group. The Consensus 
Group subsequently revised, expanded and consolidated the 
statements, ultimately providing 37 statements to start the 
Delphi process. The experts were then allocated to groups of 
four and each member also functioned as lead expert for one 
statement. Each lead expert prepared a short summary of the 
available evidence (using the papers on the central server as liter-
ature source) for this statement, which was later further updated 
based on input from other members. Statements were revised by 
the Working Group based on the feedback from the Consensus 
Group before the start of the first voting round and based on 
additional literature reviews, but also after each voting round.
Three voting rounds followed where each statement was 
presented with the evidence summary, and then the entire panel 
indicated the degree of agreement for the statement using a 
six-point Likert scale (table 1). When 80% of the Consensus 
Group agreed (A+ or A) with a statement, this was defined as 
consensus. All votes were mutually anonymous. The strength 
of evidence for each statement was scored using the grading 
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of recommendations assessment, development and evaluation 
(GRADE) system (table 2).17 All statements with grading and 
references are found in table 3.
The following statements, on relevant aspects to consider adult 
patients for antireflux surgery, were composed by the Working 
Group and reviewed and adjusted as needed by the Consensus 
Group. All statements label patients with certain characteristics 
as ‘good candidates for antireflux surgery’. This does not imply 
that surgery must be pursued in these patients, but it identifies 
them as potentially suitable for referral for surgery. Moreover, it 
is essential to understand that a decision for antireflux surgery 
based on a single characteristic (captured in a single statement) 
is also not appropriate. Referring a patient for antireflux surgery 
has to be an informed decision process, based on both positive 
and negative supporting findings.
resulTs
Clinical presentation and comorbidities
Patients with heartburn as the main symptom who respond satis-
factorily to PPIs are good candidates for antireflux surgery.
Statement endorsed, overall agreement 94.1%: A+ 67.6%, A 
26.5%, A− 5.9%, D− 0.0%, D 0.0%, D+ 0.0%; GRADE A.
The vast majority of presurgery and postsurgery studies in the 
literature enrol patients with ‘typical’ GORD symptoms which 
include both heartburn and regurgitation, as well as patients 
with GORD who have typical symptoms refractory to acid 
suppression therapy. Several peer-reviewed studies investigating 
patients who reported a complete or partial response to PPI 
therapy prior to antireflux surgery, showed a benefit of antire-
flux surgery.18–21 Moreover, the response to PPI therapy, good 
compliance and objective preoperative evidence of acid reflux 
all predict a favourable outcome.22 However, specific data on 
heartburn as the main symptom preoperatively and the response 
of heartburn symptoms to antireflux surgery were (often) not 
provided.
There is also the issue of the terminology ‘satisfactorily’, 
which is very subjective. It has indeed been shown that responses 
to satisfactorily relief could possibly be influenced by baseline 
severity.23 24 However, this terminology is easy to understand by 
patients and it fits within the practice of medicine in the office 
setting. Furthermore, in IBS therapy trials, the usefulness of 
‘satisfactorily relief ’ as an outcome parameter was linked to its 
ability to integrate various symptoms and the impact of therapy 
on various symptoms.25
2. Patients with regurgitation as the main symptom are good 
candidates for antireflux surgery, regardless of the response 
pattern to PPI therapy.
Statement not endorsed, overall agreement 79.4%: A+ 14.7%, 
A 64.7%, A−- 11.8%, D− 5.9%, D 2.9%, D+ 0.0%; GRADE B.
The ability for PPIs to adequately improve regurgitation 
appears to be much less than their ability to improve heart-
burn.26 27 In the literature, there is a lack of solid evidence to 
support the statement above. However, in a systematic analysis, 
surgery does appear to be superior to PPIs in alleviating symp-
tomatic regurgitation, although dysphagia, rectal flatulence and 
the inability to belch or vomit were significantly more common 
in patients treated surgically.8 28 29 Important to notice is that 
symptoms of regurgitation due to primary oesophageal motility 
disorders (eg, achalasia, rumination syndrome) have to be ruled 
out by means of oesophageal motility testing (preferably using 
high-resolution manometry (HRM)) before referring a patient 
for antireflux surgery.
3. Patients with reflux-hypersensitive oesophagus (normal acid 
exposure but positive symptom association with reflux events) 
are good candidates for antireflux surgery.
Statement not endorsed, overall agreement 55.9%: A+ 5.9%, 
A 50.0%, A− 26.5%, D− 11.8%, D 2.9%, D+ 2.9%; GRADE 
C.
Reflux hypersensitivity is categorised as a functional disorder 
in the latest Rome IV criteria and defined as ‘patients with 
oesophageal symptoms who lack evidence of reflux on endos-
copy or abnormal acid burden on reflux monitoring, but show 
triggering of symptoms by physiological reflux’.3 Symptoms in 
patients with reflux hypersensitivity are caused by reflux events 
(main difference with functional heartburn); therefore antire-
flux surgery can theoretically improve symptoms as it minimises 
oesophageal reflux. The majority of studies suggest that patients 
with a hypersensitive oesophagus are possibly good candidates 
for antireflux surgery,4 30–34 while a few reports suggest the 
opposite.35 More specifically, outcome in patients with hyper-
sensitive oesophagus where reflux has been documented in the 
past (either by the presence of oesophagitis or a pathological 
acid exposure time) is similar as to patients with documented 
reflux without being hypersensitive.31 32 However, a recent study 
by Patel et al showed that pure acid sensitivity was a negative 
predictor for symptom improvement with antireflux therapy, 
including surgical management.35 Moreover, patients with reflux 
hypersensitivity often display a high level of anxiety. Blondeau 
et al demonstrated that psychosocial factors and somatisation 
might contribute to symptom perception in patients with reflux 
hypersensitivity.36 This confounding factor has to be taken into 
consideration before referring these patients for antireflux 
surgery.
Table 1 Six-point Likert scale
Point Description
A+ Agree strongly
A Agree with minor reservation
A- Agree with major reservation
D- Disagree with major reservation
D Disagree with minor reservation
D+ Disagree strongly
Table 2 Grading of recommendations assessment, development and 
evaluation system16
Code
Quality of 
evidence Definition
A High Further research is very unlikely to change our confidence in 
the estimate of effect.
 ► Several high-quality studies with consistent results.
 ► In special cases: one large, high-quality multicentre trial.
B Moderate Further research is likely to have an important impact on 
our confidence in the estimate of effect and may change the 
estimate.
 ► One high-quality study.
 ► Several studies with some limitations.
C Low Further research is very likely to have an important impact on 
our confidence in the estimate of effect and is likely to change 
the estimate.
 ► One or more studies with severe limitations.
D Very low Any estimate of effect is very uncertain.
 ► Expert opinion.
 ► No direct research evidence.
 ► One or more studies with very severe limitations.
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4. Patients with functional heartburn (Rome III/IV criteria, 
who have no association of symptoms with documented episodes 
of reflux events) are poor candidates for surgery.
Statement endorsed, overall agreement 100%: A+ 91.2%, A 
8.8%, A− 0.0%, D− 0.0%, D 0.0%, D+ 0.0%; GRADE B.
Functional heartburn is defined according to the Rome IV 
criteria as ‘a burning retrosternal discomfort or pain refractory 
to optimal antisecretory therapy in the absence of gastro-oesoph-
ageal acid reflux (GOR), histopathological mucosal abnormali-
ties, major motor disorders or structural explanations’.3 In other 
words, in functional heartburn, symptoms manifest themselves 
without association to reflux events. From the mechanistic point 
of view, it is therefore unlikely that functional heartburn would 
be improved by antireflux surgery. The few available studies do 
not support the efficacy of surgery.34 37
5a. Patients with non-cardiac chest pain (NCCP) are good 
candidates for antireflux surgery only if symptoms can be 
attributed to reflux.
Statement not endorsed, overall agreement 79.4%: A+ 14.7%, 
A 64.7%, A− 14.7%, D− 2.9%, D 2.9%, D+ 0.0%; GRADE C.
NCCP is a common condition, with a prevalence of up to 
25% in the US adult population.38 After excluding a cardiac 
cause, reflux is the most common underlying mechanism for 
this disorder. Patients with NCCP might be referred to anti-
reflux surgery after ruling out oesophageal motility disorders 
such as hypercontractile oesophagus and functional chest 
pain.39 Although literature on GORD-related NCCP as the 
sole indication for surgical treatment is non-existent, fundo-
plication has been performed in this patient group. Improve-
ment after surgical treatment is better in patients with a clear 
correlation between reflux events and symptoms, in patients 
who also display typical reflux symptoms such as heartburn and 
third when there is a satisfactory response to PPIs prior to the 
surgery.40–46
5b. Patients with extra-oesophageal syndromes (asthma, 
chronic cough or laryngitis) are good candidates for antireflux 
surgery only if symptoms can be attributed to reflux.
Statement not endorsed, overall agreement 44.1%: A+ 8.8%, 
A 35.3%, A− 44.1%, D− 8.8%, D 2.9%, D+ 0.0%; GRADE C.
The vast majority of data is reported in patients with typical 
GORD symptoms and coexisting extra-oesophageal symptoms 
that seem to respond to surgery. Varying degrees of symptom 
improvement has been shown mainly in case series in respira-
tory symptoms, asthma, cough and laryngopharyngeal symp-
toms.43 47–69 Few data are available on the outcome of antireflux 
surgery for isolated atypical symptoms. Moreover, patient selec-
tion remains uncertain as there is no well-established method for 
demonstrating that these symptoms can be attributed to reflux. 
The use of symptom markers is valid for typical reflux symp-
toms; however, in case of extra-oesophageal symptoms, it has 
been subject of debate for a long time. An objective monitoring 
for chronic cough can be added through ambulatory manom-
etry or acoustic monitoring.70–73 Outcomes of Nissen fundopli-
cation in patients with chronic cough attributable to reflux were 
good although in uncontrolled and often retrospective studies, 
but these were selected patients who also displayed a positive 
pH monitoring.42 50–59 61–68 It has to be stressed out that none 
of the studies were placebo/sham controlled, which is pivotal in 
studying the exact effect of antireflux surgery in patients with 
chronic cough.
6. Patients with eosinophilic oesophagitis (EOO) on oesopha-
geal biopsies are poor candidates for antireflux surgery.
Statement endorsed, overall agreement 88.2%: A+ 61.8%, A 
26.5%, A− 8.8%, D− 2.9%, D 0.0%, D+ 0.0%. GRADE C
There is evidence in the literature that eosinophilic oesoph-
agitis in children and adults does not respond to antireflux 
surgery.74–77 Obtaining oesophageal biopsies in all patients eval-
uated for Nissen fundoplication is debatable, as reports suggest a 
low prevalence of eosinophilic oesophagitis in adults with refrac-
tory heartburn.78
7. Patients with scleroderma (and/or other severe smooth 
muscle disease) are poor candidates for antireflux surgery.
Statement not endorsed, overall agreement 64.7%: A+ 11.8%, 
A 52.9%, A− 26.5%, D− 5.9%, D 2.9%, D+ 0.0%; GRADE C.
Data on the outcome of antireflux surgery in patients with 
scleroderma (systemic sclerosis) is contradictory: there are a few 
non-randomised studies reporting (partial or full) resolution of 
reflux symptoms, while other studies suggest that surgery is of 
limited success in these patients.79–84 Although the severity of 
reflux symptoms improved after Nissen fundoplication, post-
operative dysphagia was present in 38%–71% of patients with 
scleroderma.79 81 85 A retrospective study suggested laparoscopic 
Roux-en-Y gastric bypass might be a better option in patients with 
systemic sclerosis-associated reflux: less dysphagia and improved 
reflux control was seen after Roux-en-Y gastric bypass compared 
with fundoplication.81 86 Although the oesophagus is not always 
affected in patients with systemic sclerosis, the majority of 
patients with oesophageal involvement is found to have aperi-
stalsis, which is a risk factor for postoperative dysphagia also in 
patients without scleroderma.87–89
8. Patients with concomitant functional disorders such as 
dyspepsia and IBS are good candidates for antireflux surgery, 
only if symptoms can be attributed to reflux.
Statement not endorsed, overall agreement 64.7%: A+ 23.5%, 
A 41.2%, A− 26.5%, D− 8.8%, D 0.0%, D+ 0.0%; GRADE B.
According to Rome IV criteria, functional dyspepsia (FD) is 
defined as ‘a medical condition that significantly impacts on 
the usual activities of a patient and is characterised by one of 
the following symptoms: postprandial fullness, early satia-
tion, epigastric pain or epigastric burning that are unexplained 
after a routine clinical evaluation’.90 Within patients with FD, 
a distinction between postprandial distress syndrome (PDS), 
with predominant postprandial fullness and early satiation 
and epigastric pain syndrome (EPS) characterised by epigas-
tric pain or epigastric burning is made. There are currently no 
data about the influence of Rome III/IV FD comorbidity on the 
outcome of antireflux surgery, but it may parallel the inferior 
response to PPIs.91 Studies suggest that antireflux surgery is not 
contraindicated in patients with dyspepsia comorbidity since 
these symptoms also tend to improve, but they do point out 
that the expected outcome is worse in patients with dyspepsia 
comorbidity.92
IBS is defined in the Rome IV criteria as ‘recurrent abdominal 
pain associated with defaecation or a change in bowel habits’. 
Disordered bowel habits are typically present (ie, constipation, 
diarrhoea or a mix of constipation and diarrhoea), as are symp-
toms of abdominal bloating/distention. Symptom onset should 
occur at least 6 months before diagnosis and symptoms should 
be present during the last 3 months.93 A study by Raftopoulos 
et al demonstrated that preoperative IBS is not a contraindi-
cation of antireflux surgery.94 Although Axelrod et al do not 
state that IBS is a contraindication of antireflux surgery, they 
showed that patients with a diagnosis of functional bowel 
disease or with preoperative symptoms of functional bowel 
disease were more likely to have a poor outcome compared 
with patients without the diagnosis or symptoms of functional 
bowel disease.95 The reported data—although scarce and vari-
able in quality—indicate that neither FD nor IBS comorbidity 
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is a contraindication for antireflux surgery because of a similar 
improvement of typical reflux symptoms. However, extensive 
counselling about the possibility of persistent functional GI 
symptoms and increased risk of gas-bloat syndrome postoper-
atively is warranted.
9. Patients with a body mass index >35 kg/m2 are poor candi-
dates for antireflux surgery.
Statement not endorsed, overall agreement 23.5%: A+ 2.9%, 
A 20.6%, A− 17.6%, D− 14.7%, D 38.2%, D+ 5.9%; GRADE 
B.
Obesity has been implicated as a major and independent 
risk factor for GORD by several mechanisms (increase of the 
intragastric pressure and of the abdominal–thoracic pressure 
gradient, increased gastric peptic secretion, abnormal gastric 
emptying).96 97 Losing weight should be the first pillar in GORD 
treatment for obese patients. Although Perez et al demonstrated 
that there was a 31% occurrence rate of GORD after antire-
flux surgery in 48 obese patients, other more recent studies have 
shown that preoperative obesity was not associated with a poorer 
outcome following laparoscopic Nissen fundoplication.98–102
10. Patients with psychiatric illness (major depression or 
anxiety disorder) are good candidates for antireflux surgery only 
if symptoms can be attributed to reflux.
Statement not endorsed, overall agreement 32.4%: A+ 2.9%, 
A 29.4%, A− 29.4%, D− 20.6%, D 14.7%, D+ 2.9%; GRADE 
C.
Only few studies investigated the influence of psychiatric 
comorbidity on the outcome of antireflux surgery in patients 
with GORD. It has been demonstrated that patients with GORD 
and concomitant psychiatric disorders (major depression or 
anxiety as defined by the DSM-IV) have more severe symp-
toms and lower quality of life at baseline. Even if a 24 hours 
pH-monitoring is normal after surgery, these patients report less 
symptom relief and less quality of life improvement compared 
with patients without psychiatric comorbidity.103–106
11. Patients known with substance abuse (such as alcohol 
abuse and drug abuse) are poor candidates for antireflux surgery.
Statement not endorsed, overall agreement 26.5%: A+ 8.8%, 
A 17.6%, A− 50.0%, D− 5.9%, D 17.6%, D+ 0.0%; GRADE 
D.
Alcohol and smoking may induce GOR by decreasing lower 
oesophageal sphincter (LOS) pressure and disturbance of oesoph-
ageal motility, although there is no evidence that lifestyle and 
dietary changes, for example, stopping smoking will improve 
symptoms.97 107–110 Impaired swallow-induced LOS relaxation 
and oesophageal body dysmotility were observed both in healthy 
volunteers and in symptomatic patients with dysphagia receiving 
opioids.111 112 Additionally, there is no evidence in the literature 
that all these factors may have an impact on the results of anti-
reflux surgery.113 114
12. Patients with dental erosions related to documented reflux 
are good candidates for antireflux surgery.
Statement not endorsed, overall agreement 44.1%: A+ 0.0%, 
A 44.1%, A− 29.4%, D− 8.8%, D 5.9%, D+ 11.8%; GRADE 
D.
The literature on dental erosions related to GORD is limited. 
Most studies indicate an increased prevalence of dental erosions 
in patients with GORD.115 On average, 17%–68% with GORD 
have dental erosions.116–122 A study by Wilder-Smith et al showed 
that esomeprazole 20 mg twice a day significantly reduced the 
decrease in enamel thickness compared with placebo, suggesting 
that treatment of GORD may reduce the development of 
dental erosions.119 In a 1-year follow-up study, the same group 
described no further progression in erosive tooth wear in 74% of 
the patients.123 However, to date, there are no studies available 
evaluating the effect of antireflux surgery on dental erosions.
Oesophagogastroduodenoscopy
13. Endoscopy is mandatory and has to be carried out in the last 
year prior to antireflux surgery.
Statement endorsed, overall agreement 94.1%: A+ 82.4%, A 
11.8%, A− 5.9%, D− 0.0%, D 0.0%, D+ 0.0%; GRADE B.
The literature on the use of and diagnostic output from 
endoscopy in the preoperative workup of patients with GORD 
before antireflux surgery is very extensive. Although there is no 
solid evidence that endoscopy is mandatory prior to antireflux 
surgery, there seems to be a general consensus that endoscopy 
shall be performed before antireflux surgery. The proper timing 
for endoscopy has not been studied so far and is therefore not 
well defined and the voting outcome reflects the opinion and 
clinical experience of the experts of the panel.
14. There is no need to wean the patient off PPI for an endos-
copy in the preoperative workup for antireflux surgery.
Statement endorsed, overall agreement 88.2%: A+ 41.2%, A 
47.1%, A− 2.9%, D− 5.9%, D 0.0%, D+ 2.9%; GRADE C.
The literature to support a decision on whether there is 
greater value of maintaining or for stopping PPI therapy before 
making a decision regarding selection of a patient for antire-
flux surgery is scarce. Standard current practice seems to either 
perform endoscopy on PPI or not to specify.28 124 125 The infor-
mation gained by preoperative endoscopy relates to the need to 
assess and grade dysplasia in Barrett’s oesophagus, identify the 
possibility of a short oesophagus and assess the size and config-
uration of hiatal hernia (HH).126 127 As interrupting PPI therapy 
for these assessments is unnecessary and unhelpful, patients can 
therefore continue their PPI treatment regimen for endoscopic 
assessment of reflux prior to a decision regarding the potential 
value of antireflux surgery.
15. Patients with GORD symptoms and an endoscopic diag-
nosis of a HH are good candidates for antireflux surgery.
Statement endorsed, overall agreement 82.4%: A+ 20.6%, A 
61.8%, A− 14.7%, D− 2.9%, D 0.0%, D+ 0.0%; GRADE B.
A HH disrupts the anatomy and physiology of the normal anti-
reflux mechanism (reducing the LOS length and LOS-pressure, 
impairing augmentation of the LOS by the right crus, impairing 
oesophageal peristalsis, increasing cross-sectional area of the 
oesophago-gastric junction (OGJ)). The herniated stomach acts 
as a reservoir allowing reflux into the lower oesophagus during 
swallowing. The presence of a HH is associated with increased 
symptoms of reflux, increased prevalence and severity of reflux 
oesophagitis, Barrett’s oesophagus, oesophageal adenocarci-
noma and reduced efficacy of PPI.128 129 The severity of oesoph-
agitis is best predicted by size of HH, followed by LOS pressure, 
in that order.130 Although patients with a large HH are more 
prone to have pathological reflux and more symptoms, not all 
patients with a HH have GORD.131
Up to date, there are no prospective studies reporting the 
influence of HH in recommending antireflux surgery. The Cana-
dian Consensus Conference on the management of GORD in 
adults did suggest that a significant HH, because of its likely 
contribution to reflux in an individual patient, may tip the 
balance towards surgery.132 Most series looking for independent 
predictors of success for antireflux surgery did not find presence 
of HH to be significant in multivariate analysis.10 133
16a. Patients with GORD symptoms and unequivocal pres-
ence of reflux oesophagitis Los Angeles (LA) grade A or higher 
off PPI are good candidates for antireflux surgery.
di M
ilano. Protected by copyright.
 o
n
 O
ctober 1, 2019 at UniversitÃƒÂƒÃ‚ÂƒÃƒÂ‚Ã‚ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â  degli Studi
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-318260 on 2 August 2019. Downloaded from 
7Pauwels a, et al. Gut 2019;0:1–14. doi:10.1136/gutjnl-2019-318260
Oesophagus
Statement not endorsed, overall agreement 50.0%: A+ 17.6%, 
A 32.4%, A− 47.1%, D− 2.9%, D 0.0%, D+ 0.0%; GRADE B.
16b. Patients with GORD symptoms and unequivocal pres-
ence of reflux oesophagitis LA grade B or higher off PPI are good 
candidates for antireflux surgery.
Statement endorsed, overall agreement 91.2%: A+ 47.1%, A 
44.1%, A− 8.8%, D− 0.0%, D 0.0%, D+ 0.0%; GRADE B.
Patients with GORD can be subdivided into those with erosive 
reflux disease (ERD, the presence of mucosal breaks) and those 
with non-erosive reflux disease (NERD, the absence of mucosal 
breaks) based on upper GI endoscopy findings.134 It has been 
demonstrated that progression from NERD to erosive oesoph-
agitis occurs while regression from ERD to NERD is rare.135 136 
The diminished response to medical treatment in patients with 
NERD would support a greater role for surgery in NERD than 
in ERD. It has been demonstrated that subjective and objective 
long-term outcomes of Nissen fundoplication were similar in 
ERD and NERD and results were sustained for up to 5 years 
after surgery.137 Moreover, in terms of symptoms and signs of 
erosive oesophagitis, a long-term study reported that surgery 
was superior to conservative management with modified lifestyle 
and medication.136
Historically, reflux oesophagitis off PPI was considered a 
good selection criterion, usually in combination with abnormal 
pH metry, for patient selection for an antireflux surgery. Active 
oesophagitis is a definite sign of ongoing pathological reflux and 
may help to select patients for surgery. More than 85% of the 
patients with documented oesophagitis were satisfied with the 
results of surgery (laparoscopic or open).138 However, previous 
studies demonstrated that up to 15% of the general population 
have oesophagitis LA grade A or higher. Almost half of these 
patients, in particular those with LA grade A are asymptom-
atic.2 139
Patient selection though remains mostly based on symptoms, 
as indicated by the recent LOTUS trial.8 140
17. Patients with GORD symptoms without reflux oesopha-
gitis during endoscopy performed off PPIs are poor candidates 
for antireflux surgery.
Statement not endorsed, overall agreement 2.9%: A+ 0.0%, A 
2.9%, A− 2.9%, D− 23.5%, D 44.1%, D+ 26.5%; GRADE C.
The diagnosis of NERD is based on upper GI endoscopy find-
ings and a positive pH or pH-impedance study.3 134 Impairment 
of quality of life, however, and severity of symptoms are similar 
as for ERD.141 142 In theory, the diminished response to medical 
treatment in patients with NERD could support a greater role 
for surgery in NERD than in ERD. When comparing long-term 
outcome results of antireflux surgery in patients with PPI-re-
fractory NERD and ERD, it was demonstrated that both subjec-
tive and objective long-term outcomes were similar in ERD 
and NERD and results were sustained for up to 5 years after 
surgery.32 143
18. Patients with GORD symptoms and Barrett’s oesophagus 
(non-dysplastic specialised intestinal metaplasia) on biopsies of 
the distal oesophagus are good candidates for antireflux surgery.
Statement endorsed, overall agreement 82.4%: A+ 17.6%, A 
64.7%, A− 14.7%, D− 2.9%, D 0.0%, D +0.0%; GRADE B.
The presence of Barrett’s oesophagus can be considered proof 
of the presence of GORD. Many studies confirm that antire-
flux procedures in patients with Barrett’s oesophagus effec-
tively reduce reflux-related symptoms and that uncomplicated 
Barrett’s oesophagus does not influence outcome of antireflux 
surgery.22 144–153 A meta-analysis found no evidence that antire-
flux surgery prevents the progression to carcinoma of the oesoph-
agus; therefore, postoperative endoscopic follow-up should be 
maintained.154 In patients with refractory GORD eligible for 
antireflux surgery, the presence of Barrett’s oesophagus should 
not be a contraindication. On the other hand, antireflux surgery 
should not be suggested to asymptomatic patients with Barrett’s 
oesophagus or to patients with short segment Barrett’s oesoph-
agus to prevent evolution to dysplasia or adenocarcinoma.
19. In patients considered for antireflux surgery, biopsies of 
the oesophageal body should be obtained during endoscopy.
Statement not endorsed, overall agreement 73.5%: A+ 58.8%, 
A 14.7%, A− 11.8%, D− 2.9%, D 2.9%, D+ 8.8%; GRADE C.
EOO and GORD are distinct clinical entities, theoretically 
with different pathophysiology and treatment. However, their 
differentiation may sometimes be problematic and disease 
previously thought to be associated with GORD may really 
be manifestations of EOO.155 156 Additionally, there may be a 
benefit of treatment of GORD in EOO, particularly in paediatric 
patients.157 158 Further confounding this issue of distinction is 
that patients not suspected of having EOO (those not under-
going preoperative biopsy) who receive antireflux surgery, have 
been reported to have poor outcomes.75 77 The finding of eosin-
ophils on biopsy does not necessarily confirm the diagnosis of 
EOO or exclude other oesophageal diseases, therefore rendering 
the need for mandatory biopsies questionable.159 160 It has been 
shown that cost–benefit is only present when the prevalence of 
abnormal findings is expected to be 8% or more.161
barium swallow
20. In patients with suspicion of HH or short oesophagus, a 
barium swallow is mandatory in the preoperative workup for 
antireflux surgery.
Statement endorsed, overall agreement 88.2%: A+ 44.1%, A 
44.1%, A− 5.9%, D− 2.9%, D 2.9%, D+ 0.0%; GRADE B.
It is commonly accepted that 2.5 cm of intra-abdominal 
oesophagus is necessary to perform an effective antireflux 
procedure. Today, most antireflux operations are performed 
laparoscopically. The pneumoperitoneum necessary to perform 
laparoscopy elevates the diaphragm into the mediastinum and 
appears to ‘lengthen’ the oesophagus. Failure to recognise that 
the oesophagus is shortened may result in an inadequate length 
of intra-abdominal oesophagus at surgery. If a HH repair is 
constructed under tension on a short oesophagus, the hernia is 
reduced below the diaphragm at surgery and then retracts into 
the chest over time. The fundoplication may or may not remain 
subdiaphragmatically or it may disrupt or ‘slip’ onto the stomach. 
Slipped Nissen fundoplications may therefore result from the 
failure to recognise a shortened oesophagus before surgery. The 
occurrence of the true short oesophagus is indeed thought to be 
responsible for 20%–33% of the surgical failures after open or 
laparoscopic fundoplication.162 A study by Mattioli et al demon-
strated that short oesophagus is present in about 20% of patients 
undergoing routine antireflux surgery, highlighting the impor-
tance of performing adequate testing.163
If the hernia is identified in the upright position, it is assumed 
that there is oesophageal shortening. In addition, the oesophagus 
is probably shortened when the HH length is 5 cm or greater 
alone or in combination with a stricture or a long segment 
(>3 cm) Barrett’s oesophagus.162 164 Other radiological findings 
that suggest a short oesophagus include severe extensive ulcer-
ative oesophagitis, straightening or loss of the angle of His, the 
presence of a stricture alone and type III mixed or complex 
para-oesophageal hernias.165
In summary, if endoscopy reveals the presence of a large 
hernia and/or the presence of severe oesophagitis or long 
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segment Barrett’s oesophagus, a barium swallow performed by a 
dedicated upper GI radiologist is strongly recommended before 
surgical intervention. This will allow to better plan the technical 
details of the surgery in order to eventually reduce the risk of 
anatomical and/or symptomatic recurrence.166 167
21. Patients with GORD symptoms and a small or medium 
size sliding HH on barium swallow are good candidates for anti-
reflux surgery.
Statement endorsed, overall agreement 82.4%: A+ 20.6%, A 
61.8%, A− 8.8%, D− 8.8%, D 0.0%, D+ 0.0%; GRADE B.
Very few studies have examined the effect of a HH on the 
outcome of antireflux surgery. A study by Power et al defined 
a HH size >3 cm at the time of the surgery as a predictor of 
failure.133 However, the presence and the size of a HH had 
no relationship with outcome according to several other 
studies.168–170
22. Patients with GORD symptoms and a large sliding HH on 
barium swallow are good candidates for antireflux surgery in the 
absence of short oesophagus.
Statement endorsed, overall agreement 85.3%: A+ 50%, A 
35.3%, A− 8.8%, D− 2.9%, D 0.0%, D+2.9%; GRADE B.
Upper endoscopy and barium swallow are commonly used 
to diagnose short sliding HH. It has been demonstrated that in 
morbidly obese patients, barium swallow is superior to endos-
copy in diagnosing sliding HH.171 Preoperative barium swallow 
can reveal more details on the sliding HH and contribute to 
better tailoring the antireflux surgery.166 Although there is 
currently no consensus on the definition for small, medium and 
large HH, often the cut-off of >3 cm or hernias belonging to 
categories II–IV have been used to define a large HH.94 172 173 
As 2.5 cm of intra-abdominal oesophagus is mandatory to offer 
effective antireflux surgery, in large sliding HHs (larger intra-
thoracic component), a more comprehensive dissection is 
needed.164 
23. Symptomatic patients with a para-oesophageal hernia on 
barium swallow are good candidates for antireflux surgery in 
addition to para-esophageal hernia repair.
Statement endorsed, overall agreement 97.1%: A+ 44.1%, A 
52.9%, A− 2.9%, D− 0.0%, D 0.0%, D+ 0.0%; GRADE C.
Para-oesophageal hernias (POH) are subtypes of HH, defined 
as a herniation of the peritoneal cavity into the chest through the 
diaphragmatic hiatus.
Given the difficulty of distinguishing if reflux symptoms are 
from POH alone or independent of the POH, most surgeons 
routinely add an antireflux procedure (fundoplication) after 
POH repair in elective situations.174 A recent pilot trial by 
Muller-Stich et al showed a lesser degree of reflux and a less 
oesophagitis in patients where a fundoplication was added to 
the POH repair compared with those with a POH repair only.172
Some authors advocate a selective approach to antireflux 
procedures, with preoperative testing (including manometry, 
pH-metry or endoscopy) and patient symptoms determining 
whether or not to add a fundoplication.173 Others suggest always 
performing an antireflux procedure, but tailoring the type of 
fundoplication (eg, full or partial) depending on the patient.175 
A minority suggest that fundoplication should be avoided due to 
the increased risk of dysphagia with antireflux procedures after 
POH repair.176 None of these approaches however have been 
proven superior to others in a prospective trial.
24. Patients with GORD symptoms and a short oesophagus 
on barium swallow are poor candidates for antireflux surgery.
Statement not endorsed, overall agreement 17.6%: A+ 2.9%, 
A 14.7%, A− 23.5%, D− 41.2%, D 11.8%, D+ 5.9%; GRADE 
C.
In the absence of adequate comparative studies, the ques-
tion of the short oesophagus remains controversial, and there is 
insufficient evidence to preclude patients with radiological suspi-
cion of a short oesophagus from antireflux surgery. If patients 
progress to surgery, there is also insufficient evidence to define 
the best surgical procedure in this scenario. Well-designed case–
control or randomised clinical trials are needed to provide an 
evidence base to address this question.
Oesophageal manometry
25. Oesophageal manometry is mandatory to select patients for 
antireflux surgery.
Statement endorsed, overall agreement 94.1%: A+ 82.4%, A 
11.8%, A− 5.9%, D− 0.0%, D 0.0%, D+ 0.0%; GRADE D.
Oesophageal manometry should be performed prior to anti-
reflux surgery to rule out a major motor disorder, such as acha-
lasia, OGJ outflow obstruction or absent contractility.177 178 
There is no data to support that the manometric finding of distal 
oesophageal spasm (DOS), Jackhammer oesophagus or minor 
disorders of peristalsis, such as fragmented peristalsis predicts 
postoperative dysphagia. Incorporating HRM and impedance 
into pressure flow parameters might be helpful in predicting 
outcome since the dysphagia risk index appeared to be helpful in 
identifying patients at risk for post-fundoplication dysphagia.179
26. Patients with GORD symptoms and a hypercontrac-
tile oesophagus (Jackhammer and the previously described 
Nutcracker) oesophagus on manometry are good candidates for 
antireflux surgery if symptoms can be attributed to reflux.
Statement not endorsed, overall agreement 64.7%: A+ 11.8%, 
A 52.9%, A− 29.4%, D− 2.9%, D 2.9%, D+ 0.0%; GRADE D.
Data on outcome of antireflux surgery of patients with a 
hypercontractile oesophagus is scarce: there are no randomised, 
controlled trials available in literature. However, retrospec-
tive data on outcome of patients with nutcracker oesophagus 
(although no longer defined in the Chicago classification V.3.0) 
undergoing antireflux surgery show no difference compared 
with patients with a normal oesophageal motility pattern.180 
Manometric abnormalities after a Nissen fundoplication were 
even improved in two patients with a Jackhammer oesoph-
agus.181 Hypertensive oesophageal contraction patterns are not 
a contraindication for antireflux surgery; however, patients and 
clinicians should be aware of the risk of developing chest pain 
after the surgery.182
27. Patients with GORD symptoms and distal oesophageal 
spasm on manometry are poor candidates for antireflux surgery.
Statement not endorsed, overall agreement 64.7%: A+ 
26.5%, A 38.2%, A− 20.6%, D− 11.8%, D 0.0%, D+ 0.0%; 
GRADE D.
Patients with DOS are poor candidates for antireflux surgery, 
provided that the motor disorder has been well characterised, 
preferably using HRM. Therapeutic approaches indicated 
for patients with DOS include medicines such as sildenafil, 
as well as endoscopic injection of botulin toxin and surgical 
myotomy.183–185 Although some patients may benefit from 
acid-suppressive therapy, antireflux surgery as the unique treat-
ment should be avoided in patients with DOS.
28. In patients with GORD symptoms and hypocontractility 
of the oesophageal body on manometry, antireflux surgery 
should be tailored.
Statement not endorsed, overall agreement 47.1%: A+ 5.9%, 
A 41.2%, A− 41.2%, D− 0.0%, D 5.9%, D+ 5.9%; GRADE D.
There are no good data to suggest tailoring of antireflux surgery 
to oesophageal body hypomotility or hypocontractility.186 187 
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Provocative manoeuvres during manometry could in the future 
identify patients where peristaltic performance following fundo-
plication can modify the risk for postoperative dysphagia. 
Multiple rapid swallows (MRS) are often added to the mano-
metric protocol as a marker for esophageal body peristaltic 
reserve. It has been shown that MRS testing before laparoscopic 
antireflux surgery is able to help predict late postoperative 
dysphagia.188 189
29. Patients with GORD symptoms and severe hypocontrac-
tility or failed peristalsis on manometry are poor candidates for 
antireflux surgery.
Statement not endorsed, overall agreement 64.7%: A+ 8.8%, 
A 55.9%, A− 23.5%, D− 2.9%, D 8.8%, D+ 0.0%; GRADE D.
Hypocontractility is not a contraindication for antireflux 
surgery, since surgery more often than not improved these mano-
metric abnormalities.186 Further research is warranted since very 
little data exists on outcome of patients with the most severe 
hypocontractility or aperistalsis. Similar as described above 
(statement 28) is the importance of adding MRS during a mano-
metric protocol, which is a marker of contractile reserve of the 
oesophagus.188 189 In addition, antireflux surgery can be tailored 
to each individual patient.
It has to be repeated that the main indication for manom-
etry in patients with GORD considered for antireflux surgery 
is to identify patients with aperistalsis due to achalasia, who 
are candidates for fundoplication only when combined with 
myotomy of the LOS.
reflux monitoring
30. Oesophageal pH (±impedance) monitoring off therapy is 
mandatory to select patients with NERD for antireflux surgery
Statement endorsed, overall agreement 97.1%: A+ 91.2%, A 
5.9%, A− 0.0%, D− 2.9%, D 0.0%, D+ 0.0%; GRADE B.
In the absence of oesophagitis (ie, presence of mucosal 
breaks), pathological GOR and/or positive reflux symptom asso-
ciation ‘off ’ therapy should be documented before embarking 
to antireflux surgery.22 33 190–193 In the preoperative setting, the 
added value of impedance in patients ‘off ’ therapy remains to 
be determined.
Data on preoperative assessment ‘on’ PPIs are scarce. Few 
uncontrolled and short studies suggest that good postoperative 
outcomes can be achieved in patients who are refractory to PPIs 
in whom pH-impedance monitoring demonstrated either an 
abnormal number of reflux episodes or positive symptom asso-
ciation analysis.33 194
31. Oesophageal pH (±impedance) monitoring off therapy 
should be performed for selection for antireflux surgery of 
patients who have short Barrett’s oesophagus in the absence of 
erosive oesophagitis.
Statement endorsed, overall agreement 88.2%: A+ 41.2%, A 
47.1%, A− 5.9%, D− 0.0%, D 5.9%, D+ 0.0%; GRADE B.
Oesophageal (impedance-) pH-monitoring off therapy should 
be performed in patients with short segment Barrett’s oesophagus 
as it provides an objective quantification of patient’s GOR.190 
This evaluation of PPI therapy would provide a baseline compar-
ator in assessing the efficacy of acid-suppressive therapy and/or 
reflux-reducing therapy.
32. Patients with GORD symptoms and normal reflux expo-
sure on pH (±impedance) monitoring off PPI therapy are poor 
candidates for antireflux surgery.
Statement endorsed, overall agreement 82.4%: A+ 17.6%, 
A 64.7%, A− 17.6%, D− 0.0%, D 0.0%, D+ 0.0%; GRADE 
B.
There is very limited data examining the outcomes of surgery 
in patients with normal reflux monitoring. This is in large part 
due to the fact that most of the studies evaluating outcomes 
of antireflux surgery require abnormal reflux monitoring as 
a criteria to be eligible for surgery.56 Based on the available 
evidence, it would appear that patients with normal reflux expo-
sure on pH (±impedance) monitoring off therapy are indeed 
poor candidates for antireflux surgery.
33a. Patients with GORD symptoms, a normal reflux expo-
sure on pH (±impedance) monitoring off therapy and a positive 
symptom association are good candidates for antireflux surgery.
Statement not endorsed, overall agreement 58.8%: A+ 
14.7%, A 44.1%, A− 23.5%, D− 17.6%, D 0.0%, D+ 0.0%.
33b. Patients with GORD symptoms, a normal reflux expo-
sure on pH (±impedance) monitoring off therapy and a positive 
reflux symptom association are good candidates for antireflux 
surgery, only if symptoms respond to PPI therapy.
Statement not endorsed, overall agreement 73.5%: A+ 
11.8%, A 61.8%, A− 14.7%, D− 5.9%, D 5.9%, D+ 0.0%.
There is a very limited data examining the outcomes of 
surgery in patients with normal reflux monitoring. This is in 
large part due to the fact that most of the studies evaluating 
outcomes of antireflux surgery require abnormal reflux moni-
toring as a criteria to be eligible for surgery.56 Some studies 
do suggest that reflux-hypersensitive patients with typical 
symptoms and an unsatisfactory response to PPIs may benefit 
from antireflux surgery with an outcome similar to the one of 
patients with pathological reflux.31 195 However, as mentioned 
above (statement 3), a recent study by Patel et al showed that 
pure acid sensitivity was a negative predictor for symptom 
improvement with antireflux therapy, including surgical 
management.35 Results should therefore be interpreted with 
caution.
34a. Patients with GORD symptoms and pathological reflux 
exposure on pH (±impedance) monitoring off therapy and a 
negative reflux symptom association are eligible for antireflux 
surgery.
Statement not endorsed, overall agreement 58.8%: A+ 5.9%, 
A 52.9%, A− 29.4%, D− 8.8%, D 2.9%, D+ 0.0%.
34b. Patients with GORD symptoms and pathological reflux 
exposure on pH (±impedance) monitoring off therapy and a 
negative reflux symptom association are eligible for antireflux 
surgery, only if symptoms respond to PPI therapy.
Statement not endorsed, overall agreement 66.7%: A+ 6.1%, 
A 60.6%, A− 9.1%, D− 6.1%, D 18.2%, D+ 0.0%.
The literature available suggests that patients with proven 
pathological acid exposure who do not experience symptoms 
during pH (±impedance) monitoring or presenting a negative 
symptom–reflux association may still obtain good results from 
anti-reflux surgery.33 192 Moreover, there is a subgroup of patients 
that is truly refractory to PPIs, with ongoing acid secretion.193
35. Patients with pathological reflux exposure on pH (±imped-
ance) monitoring on PPI who respond to baclofen therapy are 
good candidates for antireflux surgery.
Statement not endorsed, overall agreement 20.6%: A+ 5.9%, 
A 14.7%, A− 61.8%, D− 2.9%, D 11.8%, D+ 2.9%.
Baclofen, a GABA B-agonist, is known to reduce the number 
of transient LOS relaxations and subsequently, it reduces all 
types of reflux, including weakly acidic reflux.196 To date, there 
are no studies comparing baclofen with antireflux surgery, there-
fore it would be too speculative to say that patients responding 
to baclofen are good candidates for antireflux surgery. In the 
very recently published paediatric GOR clinical guidelines, the 
use of baclofen prior to antireflux surgery can be considered in 
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children in whom other pharmacological treatments have failed 
(weak recommendation).197
Gastric emptying
36. A gastric emptying test for solid food is necessary to select 
patients with GORD with concomitant dyspeptic symptoms for 
antireflux surgery.
Statement not endorsed, overall agreement 5.9%: A+ 2.9%, 
A 2.9%, A− 8.8%, D− 5.9%, D 67.6%, D+ 11.8%; GRADE C.
Studies performed to assess the role of a preoperative gastric 
emptying test in antireflux surgery have generated controversial 
results: some studies have shown that this evaluation is useful 
to select the best type of surgery and to avoid surgical failures, 
while others have denied the validity of such an approach.198–200 
However, so far no study has been performed to establish 
whether the assessment of gastric emptying is relevant or not to 
favour success of surgery in patients with GORD with concomi-
tant dyspepsia symptoms.
37. If the gastric emptying test is abnormal for solid food, 
patients should not undergo an antireflux surgery.
Statement not endorsed, overall agreement 2.9%: A+ 0.0%, 
A 2.9%, A− 0.0%, D− 20.6%, D 67.6%, D+ 8.8%; GRADE C.
Literature shows that there is no evidence to suggest that preop-
erative slow gastric emptying for solids is associated with a poor 
outcome after surgery with regard to reflux parameters.201 202 A 
study by Lundell et al suggests that a slow preoperative gastric 
emptying for solids is weakly associated with symptoms of 
bloating.202 However, two other studies investigating the rela-
tionship between gastric emptying rates before and outcome 
after antireflux surgery could not confirm this.198 199 There is 
insufficient evidence to support the statement.
recommendations
Based on the statements that generated consensus, a number of 
recommendations can be made for selecting patients for antire-
flux surgery. These are summarised in table 4.
The Delphi process also identified several areas of uncer-
tainty, requiring further research. It is unclear whether patients 
with regurgitation as a main symptom, patients with NCCP, 
patients with extra-oesophageal manifestations of reflux and 
patients with dental erosions are good candidates for anti-reflux 
surgery (statements 2, 5 and 12). There is a lack of prospective 
controlled trials to support these statements. Patients with reflux 
hypersensitivity, patients with concomitant FD and IBS and 
patients with major psychiatric comorbidity are not considered 
good candidates for antireflux surgery (statements 3, 8 and 10). 
There is a need for additional markers of beneficial outcome of 
antireflux surgery in these patients, given the frequent overlap 
of GORD with FD and IBS symptoms. There is no consensus 
that patients with scleroderma are poor candidates for antireflux 
surgery (statement 7). It is unclear to which extent patients with 
Jackhammer (or Nutcracker) oesophagus or spasm on manom-
etry are eligible for antireflux surgery (statements 26 and 27). 
The impact of oesophageal hypocontractility on the eligibility 
or type of antireflux surgery is unclear (statements 28 and 29). 
It is unclear whether patients with reflux hypersensitivity are 
eligible for antireflux surgery (statement 33). Finally, it is unclear 
whether patients with pathological reflux monitoring but nega-
tive symptom association are good candidates for antireflux 
surgery (statement 34).
It is important to stress that the decision of referring a patient 
for antireflux surgery has to take into account all positive as well 
as all negative support findings. Selecting patients suitable for 
antireflux surgery cannot be captured by one single statement 
and remains subject to guided clinical judgement and patient 
preference.
COnClusIOn
GORD, often accompanied by the typical reflux symptoms 
heartburn and regurgitation or by atypical reflux symptoms such 
as chronic cough and wheezing, is very common in the Western 
World.1 2 The first-line treatment for GORD is acid suppres-
sive therapy, most often by PPI intake. PPIs have shown to be 
very effective in healing oesophagitis, however up to 40% of 
patients with GORD remain symptomatic while on an adequate 
dose of PPIs.5 6 Antireflux surgery is often recommended for 
patients with insufficient relief of symptoms during PPI intake, 
in case of intolerance to or anticipated long-term use of PPIs. 
However, to date, consensus guidelines defining clinical criteria 
and additional technical examinations that need to be performed 
for patient selection for antireflux surgery are lacking. There-
fore, we aimed to develop the ICARUS guidelines using a Delphi 
process.
The Consensus Group defined several statements that may 
guide clinicians and surgeons in their decision to select patients 
for antireflux surgery. All patients require endoscopy, pH-mon-
itoring off PPI and oesophageal manometry. The consensus 
Table 4 Summary of the ICARUS guidelines
recommendations
based on 
statement(s)
Antireflux surgery can be considered for patients with typical 
symptoms of heartburn, with a good response to proton pump 
inhibitors (PPIs).
1
Patients with functional heartburn and patients with eosinophilic 
oesophagitis are poor candidates for antireflux surgery.
4, 6
Patients with morbid obesity and patients with substance abuse 
are not excluded from antireflux surgery.
9, 11
Endoscopy (during the last year) is mandatory prior to referral for 
antireflux surgery. There is no need to wean the patient off PPI for 
endoscopy.
13, 14
Patients with GORD symptoms and a hiatal hernia, Barrett’s 
oesophagus or erosive oesophagitis grade B or higher at 
endoscopy are good candidates for antireflux surgery.
15, 16b, 18
Patients without erosive oesophagitis are not excluded from 
antireflux surgery.
17
There is no need to obtain routine biopsies of the distal 
oesophagus in patients considered for antireflux surgery.
19
A barium X-ray should be obtained in patients with suspicion of a 
hiatal hernia or short oesophagus when considered for antireflux 
surgery.
20
Patients with GORD symptoms and a hiatal hernia on X-ray are 
good candidates for antireflux surgery.
21, 22
Patients with GORD symptoms and a para-oesophageal hernia 
on X-ray are good candidates for antireflux surgery in addition to 
para-oesophageal hernia repair.
23
A short oesophagus on barium X-ray does not exclude the patient 
from antireflux surgery.
24
Oesophageal manometry and oesophageal pH monitoring 
(±impedance) are mandatory prior to referral for antireflux surgery. 
The latter is preferentially done off PPI and in patients with NERD.
25, 30, 31
Patients with normal pH-monitoring off PPI are poor candidates for 
antireflux surgery.
32
Response to baclofen does not enhance patient eligibility for 
antireflux surgery.
35
There is no need to assess gastric emptying rate in patients 
considered for antireflux surgery.
36, 37
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process also identified areas of uncertainty and some patient 
groups in whom referral for surgery should be avoided, such as 
functional heartburn.
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